This trial is testing a new drug for people with multiple myeloma that has come back or does not respond to treatment.
4 Primary · 16 Secondary · Reporting Duration: Up to 60 months
Experimental Treatment
220 Total Participants · 1 Treatment Group
Primary Treatment: CC-93269 · No Placebo Group · Phase 1
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: